MedTrace Logo

Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease

NCT05703919 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1888

Last updated 2025-06-10

No results posted yet for this study

Summary

The STOP-COPD trial is a randomized, patient-blinded, prehospital clinical trial designed to evaluate the effect of titrated oxygen therapy compared to standard oxygen treatment in patients with suspected acute exacerbation of chronic obstructive pulmonary disease (AECOPD) treated with inhaled bronchodilators. The primary objective is to determine whether a titrated oxygen strategy targeting SpO₂ 88-92% can reduce 30-day mortality compared to the current standard practice using 100% compressed oxygen as a nebulizer driver.

Conditions

  • COPD Exacerbation
  • COPD Exacerbation Acute

Interventions

DRUG

Titrated Oxygen

Titrated oxygen strategy - a mix of supplemental oxygen and compressed atmospheric air as driver for inhaled bronchodilators to target SpO2 88-92%

DRUG

Standard Oxygen

Standard care using compressed oxygen (100%) as driver for inhaled bronchodilators

Sponsors & Collaborators

  • Central Denmark Region

    lead OTHER

Principal Investigators

  • Martin F Gude, PhD · Central Denmark Region

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-02
Primary Completion
2027-05-31
Completion
2028-05-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05703919 on ClinicalTrials.gov